SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The ticket is $Testicle. EVERY SINGLE ONE OF YOU CAME FROM A $Testicle. $Testicle always bounce.   We have a website on which you can create art or memes. We have a community. We have a raid group. We aim to provide the best testicular care on CT.   We might even have to call on our nefarious leader, Harry Bolz. Alright Chad, SACK TF. Or else you’re a Low T beta male.   If you have questions and or concerns please feel to reach out to a team member on how you can acquire or become a high testosterone male in a sea of betas. I mean how else does one live if not as a High T male?

Testicle

TESTICLE CRYPTO is trending due to its highly provocative name, sparking widespread disbelief and drawing comparisons to other humorously named meme coins in the community. Investors are actively discussing its perceived absurdity, with some humorously embracing its speculative nature while others decry it as a prime example of the market's increasing embrace of joke assets and potential scams.

Alchemy Pay

Alchemy Pay (ACH) is seeing increased attention following its integration with Ripple's RLUSD stablecoin, significantly expanding its global fiat on-ramp capabilities. Further fueling community discussion are reports of Alchemy Pay securing its tenth U.S. Money-Transmitter License and a whitepaper outlining its shift towards a stablecoin-focused Layer1 blockchain, driving optimism for its compliant, enterprise-grade payment solutions and potential for future growth.

Journey Medical Corp. is a commercial-stage pharmaceutical company, which focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Its brands include QBREXZA, Accutane, Targadox, AMZEEQ, Ximino, ZILXI, Exelderm, and Luxamend. The company was founded by Claude Maraoui in October 2014 and is headquartered in Scottsdale, AZ.

Journey Medical Corp

Journey Medical Corp. is trending following the FDA approval and anticipated commercial launch of its rosacea drug, Emrosi (DFD-29), a development significantly bolstered by a recent black box warning for competitor Oracea. Investors are highly optimistic about Emrosi's potential as a best-in-class, standard-of-care treatment, with many seeing the stock as deeply undervalued given its revenue and profitability prospects. The community is now focused on an upcoming commercialization call for key details regarding market launch and financial outlook, which is expected to clarify its path to significant growth.

Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. It is a clinical-stage cell therapy company that combines a novel patient engineering approach with therapies to provide a single company solution for patients suffering from hematological malignancies. The company was founded by Aleks Radovic-Moreno and Siddhartha Mukherjee on December 30, 2015 and is headquartered in Boston, MA.

Vor Biopharma Inc

Vor Biopharma is trending following major analyst endorsements, including an "Overweight" rating and a substantial price target from JPMorgan, coupled with a "Buy" rating from TD Cowen. The community is actively debating the significant upside potential, fueled by its lead autoimmune drug's recent Phase 3 clinical success and strategic financing, while also acknowledging its characteristic volatility.

Wishing Well

WISH CRYPTO is gaining significant attention from its community, fueled by an active weekend contest, continuous vision updates on X, and anticipation for its chart to go fully live on major platforms. Investors are discussing its unique deflationary tokenomics, which includes monthly burns tied to US inflation, and its strong community backing as a long-term HODL opportunity that stands apart from typical memecoins.

Invesco DB US Dollar Index Trust - Invesco DB US Dollar Index Bullish Fund

Invesco DB US Dollar Index Bullish Fund

The Invesco DB US Dollar Index Bullish Fund (UUP) is trending as market participants keenly debate the Federal Reserve's monetary policy path, widely anticipating rate cuts that could pressure the dollar. Despite this, a notable segment of the community is actively buying UUP calls, anticipating a potential flight to safety amidst global market uncertainties and diverging central bank actions.

Grok's first token launched on Base, deployed directly on X with help of Bankr. Proof of deployment here, https://x.com/grok/status/1897949874961650169.  Join the DRB community if this story intrigues you, follow it as it unfolds into this new AI era.  Grok earns swap fees - Grok's trading wallet: 0xb1058c959987e3513600eb5b4fd82aeee2a0e4f9.  Articles, media coverages on $DRB featured here, https://linktr.ee/DRBtaskforce.  Our dev, is grok, one of the front-running candidate to achieve AGI.

DebtReliefBot

DRB CRYPTO (DebtReliefBot) is gaining significant attention within the crypto community, driven by its unique identity as an AI-to-AI generated token with strong perceived ties to Grok. Enthusiasts are highlighting its current low market capitalization, suggesting it holds considerable growth potential as a "sleeper" asset in the expanding AI and Base/Farcaster ecosystem.

Braze, Inc. operates a customer relationship management platform for mobile applications. Its application combines messaging, audience segmentation, analytics and user support in a single integrated solution. The firm offers push notifications, email, in-app messages, and news feed services. The company was founded by Mark Ghermezian, William Magnuson, and Jonathan Hyman in 2011 and is headquartered in New York, NY.

Braze Inc - Ordinary Shares - Class A

Braze Inc

Braze is trending due to a robust earnings report that exceeded expectations and included raised full-year guidance, which spurred a wave of analyst upgrades and increased price targets. While many in the community are bullish on its customer engagement platform, citing strong growth, AI integration, and a recent acquisition as catalysts for a potential breakout or buyout, others remain highly skeptical about its long-term profitability and competitive landscape.

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Seres Therapeutics Inc

Seres Therapeutics is trending due to heightened speculation surrounding an imminent buyout, particularly from Nestl, fueled by its limited cash runway and recent scientific publications validating its microbiome platform. While long-term investors express deep frustration over management's perceived lack of transparency, the community remains actively engaged in discussions about a potential acquisition or significant partnership.

Direxion Shares ETF Trust - Direxion Daily S&P Oil & Gas Exp. & Prod. Bull 2X Shares

Direxion Daily S&P Oil & Gas Exp. & Prod. Bull 2X Shares

GUSH is trending as intensifying geopolitical developments in the Middle East dominate investor conversation, with particular focus on potential impacts to global oil supply and shipping routes. The community is keenly observing how these events, alongside anticipated shifts in energy policy, could influence this leveraged oil and gas exploration and production ETF. Many anticipate significant price action, reflecting its inherent volatility and sensitivity to market catalysts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is Lyft a Buy Going Into 2026?

Key PointsThe ride-hailing service enters 2026 on a much stronger footing...

Harel Insurance Investments & Financial Services Ltd. Has $8.14 Million Stake in Lyft, Inc. $LYFT

Harel Insurance Investments & Financial Services Ltd. reduced its holdings in shares of Lyft, Inc. (NASDAQ:LYFT - Free Report) by 14.7% in the 3rd quarter, according to its most recent filing with...

63,504 Shares in Lyft, Inc. $LYFT Acquired by Aviance Capital Partners LLC

Aviance Capital Partners LLC bought a new stake in Lyft, Inc. (NASDAQ:LYFT - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities...

Gig Economy Stocks Worth Buying Now As the Theme Gains Popularity

ANGI, AMZN and UBER are tapping into the booming gig economy with platforms that empower flexible, on-demand work.

Lyft (LYFT) Outperforms Broader Market: What You Need to Know

In the latest trading session, Lyft (LYFT) closed at $19.7, marking a +2.52% move from the previous day.

Cerity Partners LLC Has $14.88 Million Position in Lyft, Inc. $LYFT

Cerity Partners LLC boosted its holdings in Lyft, Inc. (NASDAQ:LYFT - Free Report) by 22.6% during the third quarter, according to the company in its most recent filing with the Securities and...

Lyft and Uber drivers protest Waymo robotaxis as California considers further regulations

Lyft and Uber drivers protested Waymo's self-driving taxis in San Francisco...

Rheos Capital Works Inc. Sells 1,000,000 Shares of Lyft, Inc. $LYFT

Rheos Capital Works Inc. trimmed its stake in Lyft, Inc. (NASDAQ:LYFT - Free Report) by 42.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and...

<ul class="summary-bullets"><li>Nvidia is offering the full self-driving “brain” for the first time, with real-world performance yet to be proven at scale, according to Altimeter’s Freda Duan.</li><li>Duan highlighted differences in training spend and data disclosures between Nvidia and Tesla.</li><li>Duan said on-road deployments will be the key signal for evaluating Nvidia’s approach.</li></ul><p>Freda Duan, a partner at Altimeter Capital, said Nvidia’s move to offer a full, end-to-end autonomous driving stack has introduced new uncertainty into how the market values Tesla’s&nbsp;self-driving story, potentially leaving the EV maker trading with a higher, sentiment-driven discount rate.</p><h2 class="st-heading-2"><strong>Nvidia’s Shift From Chips To A Full AV Stack</strong></h2><p>Duan described Nvidia’s&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/FredaDuan/status/2008677250363719703">latest push on X</a> as a potential “Android moment” for self-driving if it succeeds, referring to the possibility that a broadly available, full autonomy “brain” could reshape how autonomous technology is adopted across the industry.</p><p>She said Nvidia has been involved in autonomous driving for years with mixed results, but that this marks the first time the company is offering the full decision-making system, rather than only the picks-and-shovels infrastructure stack. Duan added that whether Nvidia’s model performs at production-grade levels across real-world edge cases remains an open question until it is tested on the road at scale.</p><p>Her comments come as Nvidia broadens its autonomous driving push alongside new AI hardware. At the Consumer Electronics Show in Las Vegas, Nvidia CEO Jensen Huang said the company’s next-generation Vera Rubin chips are in full production and highlighted Alpamayo, a suite of autonomous driving models, simulation tools and datasets designed to help vehicles reason through complex road scenarios.&nbsp;</p><p>Nvidia said Alpamayo and the data used to train it will be released more broadly so automakers can evaluate performance.</p><h2 class="st-heading-2"><strong>Training Spend And Long-Term Economics</strong></h2><p>Duan said Tesla’s self-driving training spend is estimated at $3 billion - $4 billion in fiscal 2024, with roughly $5 billion per year likely required to sustain its edge. She said that if Nvidia’s approach is successful, Tesla’s terminal market share will likely go down.</p><p>She noted that many vehicles currently on the road are equipped with only one or two cameras, adding that hardware readiness remains a factor. She said these constraints are expected to change over time and added that Chinese automakers do not face the same limitations.</p><p>Duan also said broader access to autonomy platforms could have implications for ride-hailing-style networks such as Uber and Lyft.</p><h2 class="st-heading-2"><strong>Tesla’s Chip Roadmap&nbsp;</strong></h2><p>Duan’s remarks come alongside Tesla’s ongoing work on custom AI hardware. Tesla’s vehicles currently&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-ai-chief-reveals-ai-4-power-jump-as-ceo-musk-eyes-building-more-intelligent-chips-than-all-rivals-combined/cL5GU9HREfS">use the AI4 processor, with AI5 close to tape-out and AI6 already in development</a>, as part of a plan to introduce new chip designs annually.</p><p>Tesla CEO Elon Musk has also said that&nbsp;the company&nbsp;may need to build a “gigantic” semiconductor fabrication plant to meet future demand from its autonomous driving and robotics programs, citing potential output limitations from existing manufacturing partners.</p><h2 class="st-heading-2"><strong>What The Market Is Watching Next</strong></h2><p>Duan said the real answer to the debate around Nvidia’s approach will come from on-road performance rather than model papers or theoretical discussions. She said the first meaningful signal will be the Mercedes-Benz CLA deployments expected in 2026.</p><p>Until then, Duan said most conclusions remain educated guesswork, and added that self-driving remains frontier technology, with no clear consensus on long-term market penetration or sustainable market share for any single player, and said new information that materially shifts expectations is likely to amplify volatility.</p><h2 class="st-heading-2"><strong>How Did Stocktwits Users React?</strong></h2><p>On Stocktwits, retail sentiment on Tesla was ‘extremely bearish’, while sentiment on Nvidia was ‘bullish’, with message volume described as ‘high’ for both stocks.</p><p>While&nbsp;<a href="https://stocktwits.com/symbol/TSLA">Tesla’s stock</a> has risen 5% over the past 12 months,&nbsp;<a href="https://stocktwits.com/symbol/NVDA">Nvidia’s stock</a> has jumped 30% over the same period.&nbsp;</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, a Nvidia logo is seen displayed on a smartphone with a Tesla logo in the background. (Photo Illustration by Avishek Das/SOPA Images/LightRocket via Getty Images)

Is Tesla’s Autonomy Premium At Risk? This Analyst Says Nvidia’s Full Self-Driving Stack Leaves EV Maker Trading On Sentiment

Altimeter Capital’s Freda Duan said broader access to Nvidia’s full self-driving stack could change how autonomy is adopted across the industry.

Equity

Lyft (LYFT) Stock Drops Despite Market Gains: Important Facts to Note

In the closing of the recent trading day, Lyft (LYFT) stood at $19.15, denoting a -3.23% move from the preceding trading day.

Lyft, Inc. engages in the provision and management of an online social rideshare community platform. It offers access to a network of shared bikes and scooters for shorter rides and first mile and last-mile legs of multimodal trips, information about nearby public transit routes, and Lyft Rentals to offer riders a view of transportation options when planning any trip. The company was founded by Marcus Cohn, John Zimmer, Rajat Suri, Matt van Horn, and Logan Green in 2007 and is headquartered in San Francisco, CA.

Current Price	$18.33
Prev Close	$18.88
Open	$18.82
Dividend Yield	0.00%
50-Day Moving Average	$20.60
Beta	1.67
Avg. Volume	11.49M
PE Ratio	50.82

52-Week High	$25.54
52-Week Low	$9.66
Market Capitalization	$7.32B
EPS (Annual)	$0.0551
Price to Book	12.84
Revenue Per Employee	$1.97M
Enterprise Value/EBITDA	N/A

LYFT
Lyft Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest LYFT News

LYFTLyft Inc